We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

287% more call options, than puts

Call options by funds: $22.4M | Put options by funds: $5.79M

77% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 57

1% more capital invested

Capital invested by funds: $1.23B → $1.24B (+$18.3M)

0.61% more ownership

Funds ownership: 92.14% → 92.75% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

1% less funds holding

Funds holding: 236 → 233 (-3)

Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M

Top Buyers

1
B
Braidwell
Connecticut
+$18.5M
2
DM
Deerfield Management
New York
+$14.1M
3
N
Nuveen
North Carolina
+$11.3M
4
BlackRock
BlackRock
New York
+$9.19M
5
Morgan Stanley
Morgan Stanley
New York
+$6.87M

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.3M
2
State Street
State Street
Massachusetts
-$12.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.95M
4
Fisher Asset Management
Fisher Asset Management
Washington
-$8.19M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$119M +$9.19M +1,278,601 +8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$109M +$2.17M +302,270 +2%
BBA
3
Baker Bros. Advisors
New York
$90M – – –
ACA
4
Avoro Capital Advisors
New York
$81.8M -$3.63M -505,000 -4%
State Street
5
State Street
Massachusetts
$74.1M -$12.9M -1,797,591 -15%
B
6
Braidwell
Connecticut
$38M +$18.5M +2,571,100 +92%
Millennium Management
7
Millennium Management
New York
$35.3M -$2.29M -318,813 -6%
Pictet Asset Management
8
Pictet Asset Management
Switzerland
$29.7M +$30.1M +4,192,300 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$27.7M +$564K +78,522 +2%
RM
10
RP Management
New York
$27.2M – – –
DM
11
Deerfield Management
New York
$23.3M +$14.1M +1,964,000 +149%
Fisher Asset Management
12
Fisher Asset Management
Washington
$22.6M -$8.19M -1,139,354 -26%
KCM
13
Kynam Capital Management
New Jersey
$22.2M +$2.05M +284,996 +10%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$20.9M +$25.7K +3,575 +0.1%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$19.5M -$8.95M -1,245,887 -31%
N
16
Nuveen
North Carolina
$18.2M +$11.3M +1,577,857 +159%
GKIM
17
GW&K Investment Management
Massachusetts
$18.2M -$197K -27,379 -1%
RSCM
18
Rock Springs Capital Management
Maryland
$18.1M +$388K +54,033 +2%
EP
19
Eversept Partners
New York
$17.6M +$769K +106,990 +5%
PM
20
Prosight Management
Texas
$17M -$660K -91,865 -4%
BNP Paribas Asset Management
21
BNP Paribas Asset Management
France
$16.9M -$138K -19,242 -0.8%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$16.8M +$1.66M +231,300 +11%
RHJA
23
Rice Hall James & Associates
California
$16.1M +$2.89M +402,674 +21%
SBH
24
Segall Bryant & Hamill
Illinois
$14.3M -$142K -19,702 -1%
EAM
25
Eventide Asset Management
Massachusetts
$13.9M – – –
1
2 3 4 5

BCRX Hedge Fund Activity: Q3 2023 in Review

233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2023, worth a combined $1.24B — up 1.5% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 101 added.

The largest buyer was Braidwell, adding an estimated $18.5M. The largest seller was Assenagon Asset Management, cutting an estimated $30.3M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2023, down from 236 in Q2 2023.
  • Funds reported $1.24B of BioCryst Pharmaceuticals stock for Q3 2023, up 1.5% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2023 was Braidwell, an estimated $18.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2023.